Looking forward, we will deliver on the great promise in our specialty and generic pipelines and in the intersections between them. We are taking bold steps forward to create a new future for Teva, fuelled by our passion to meet patients' needs worldwide.
“We are creating breakthroughs in neurodegeneration. Teva’s National Network of Excellence will contribute to the quality of life of us all.”
“Copaxone and Azilect came from Israeli universities. Why wouldn’t we tap into this incredible expertise and innovation of Israeli Universities to find the next jewels.”
"Our single-minded focus, through the skills of our scientists, is to ensure that we bring essential generic medicines of high quality to the greatest number of in the fastest time possible."
“Today we can understand the processes resultingin disease and response to drugs in individual patients with greater precision than ever before.”
“Our NTE process reflects our expertise ingenerics and specialty drugs, and the synergiescreated when these capabilities are integrated.”
"Our collaboration with Teva will contribute greatly to the Korean pharmaceutical industry by supplying innovative medicines at affordable prices."
“In China there is an increasing demand forquality generic medication. We were very impressedby Teva's oncology, CNS and respiratory portfolio."
“Our DNA is the combination of P&G and Teva. Our mission is to understand what people wantand need, and then find innovative ways to deliver that.”
“We are excited to develop environmentally friendly technologies to create a healthier world for our customers worldwide.“
All News › Top News Teva Updates Announced Tender Offers Feb. 27, 2015 – Teva announces early tender results, applicable Reference Yields and consideration payable for previous tender offers. Discover more Share Top News FDA Accepts Hydrocodone Bitartrate NDA Feb. 25, 2015 – The FDA has accepted for review Teva’s NDA for investigational Hydrocodone Bitartrate ER tablets with proprietary abuse deterrence technology. Discover more Share Top News Positive Results for TEV-48125 in Phase IIb Study Feb. 24, 2015 - Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints. Discover more Share Top News Positive Reslizumab Phase III Data Published Feb. 23, 2015 - The Lancet Respiratory Medicine and AAAAI publish positive data from Phase III trials of Teva’s Reslizumab. Discover more Share
Top News Teva Updates Announced Tender Offers Feb. 27, 2015 – Teva announces early tender results, applicable Reference Yields and consideration payable for previous tender offers. Discover more
Top News FDA Accepts Hydrocodone Bitartrate NDA Feb. 25, 2015 – The FDA has accepted for review Teva’s NDA for investigational Hydrocodone Bitartrate ER tablets with proprietary abuse deterrence technology. Discover more
Top News Positive Results for TEV-48125 in Phase IIb Study Feb. 24, 2015 - Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints. Discover more
Top News Positive Reslizumab Phase III Data Published Feb. 23, 2015 - The Lancet Respiratory Medicine and AAAAI publish positive data from Phase III trials of Teva’s Reslizumab. Discover more
New Plant in Germany With the press of a button, Germany’s Federal Minister of Health Daniel Bahr recently started up the first production line in the newly-built sterile production plant at Teva’s site in Blaubeuren-Weiler. Discover more
With the press of a button, Germany’s Federal Minister of Health Daniel Bahr recently started up the first production line in the newly-built sterile production plant at Teva’s site in Blaubeuren-Weiler.
National Multiple Sclerosis Society Honors Teva On December 3, the National Multiple Sclerosis Society honored Teva for its contributions at an Awards Dinner in Philadelphia for participation in the Bike MS: City to Shore 2014 event. Discover more
On December 3, the National Multiple Sclerosis Society honored Teva for its contributions at an Awards Dinner in Philadelphia for participation in the Bike MS: City to Shore 2014 event.
New R&D Center in Croatia The President of the Republic of Croatia, Dr. Ivo Josipović, officially opened Teva’s new R&D extension at PLIVA. Discover more
The President of the Republic of Croatia, Dr. Ivo Josipović, officially opened Teva’s new R&D extension at PLIVA.
How Our Uniqueness Creates Healthcare Confidence Around the world, people know that our ultimate goal is their health and well-being. Find out how we do it:
Around the world, people know that our ultimate goal is their health and well-being. Find out how we do it: